Page last updated: 2024-12-11
l 689502
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
L 689502: HIV-1 protease inhibitor; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
ID Source | ID |
---|---|
PubMed CID | 5464037 |
CHEMBL ID | 2062158 |
SCHEMBL ID | 6366451 |
MeSH ID | M0195515 |
Synonyms (19)
Synonym |
---|
tert-butyl n-[(2s,3s,5r)-3-hydroxy-5-{[(1s,2r)-2-hydroxy-2,3-dihydro-1h-inden-1-yl]carbamoyl}-5-({4-[2-(morpholin-4-yl)ethoxy]phenyl}methyl)-1-phenylpentan-2-yl]carbamate |
bdbm881 |
l-685,434 derivative |
n-(2(r)-hydroxy-1(s)-indanyl)-5(s)-[(tert-butyloxycarbonyl)amino]-4(s)-hydroxy-6-phenyl-2(r)-[[4-[2-(4-morpholinyl)ethoxy]phenyl]methl]hexanamide |
n-(2(r)-hydroxy-1(s)-indanyl)-5(s)-[(tert-butyloxycarbonyl)amino]-4(s)-hydroxy-6-phenyl-2(r)-[[4-[2-(4-morpholinyl)ethoxy]phenyl]methyl]hexanamide |
tert-butyl n-[(1s,2s,4r)-1-benzyl-2-hydroxy-5-[[(1s,2r)-2-hydroxyindan-1-yl]amino]-4-[[4-(2-morpholinoethoxy)phenyl]methyl]-5-oxo-pentyl]carbamate |
l-689,502 |
138483-63-3 |
l 689502 |
tert-butyl n-[(2s,3s,5r)-3-hydroxy-6-[[(1s,2r)-2-hydroxy-2,3-dihydro-1h-inden-1-yl]amino]-5-[[4-(2-morpholin-4-ylethoxy)phenyl]methyl]-6-oxo-1-phenylhexan-2-yl]carbamate |
carbamic acid, (5-((2,3-dihydro-2-hydroxy-1h-inden-1-yl)amino)-2-hydroxy-4-((4-(2-(4-morpholinyl)ethoxy)phenyl)methyl)-5-oxo-1-(phenylmethyl)pentyl)-, 1,1-dimethylethyl ester, (1s-(1alpha(1r*,2r*,4s*),2alpha))- |
carbamic acid, ((1s,2s,4r)-5-(((1s,2r)-2,3-dihydro-2-hydroxy-1h-inden-1-yl)amino)-2-hydroxy-4-((4-(2-(4-morpholinyl)ethoxy)methyl)-5-oxo-1-(phenylmethyl)pentyl)-, 1,1-dimethylethyl ester |
l-689502 |
CHEMBL2062158 |
SCHEMBL6366451 |
DTXSID40160692 |
CS-7476 |
HY-U00261 |
AKOS040741926 |
Research Excerpts
Dosage Studied
Excerpt | Relevance | Reference |
---|---|---|
" These changes occurred rapidly, with elevations in serum transaminase observed as early as 6 hr after oral dosing in dogs." | ( Hepatotoxicity of an HIV protease inhibitor in dogs and rats. Alberts, DW; Anderson, C; Eydelloth, RS; Grossman, SJ; Patrick, DH; Reinford, N; Smith, PF, 1997) | 0.3 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Protein Targets (2)
Inhibition Measurements
Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
Gag-Pol polyprotein | Human immunodeficiency virus type 1 (NEW YORK-5 ISOLATE) | IC50 (µMol) | 0.0004 | 0.0002 | 0.1042 | 1.7000 | AID1795281 |
Protease | Human immunodeficiency virus 1 | IC50 (µMol) | 0.0004 | 0.0001 | 0.2248 | 7.3200 | AID162043; AID162181 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Bioassays (19)
Research
Studies (11)
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 10 (90.91) | 18.2507 |
2000's | 1 (9.09) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 11.96
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (11.96) All Compounds (24.57) |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 11 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |